The original trial design for the BTT arm called for enrollment of 133 patients. As of April 27, 2007, the company reported that it had enrolled 296 patients in the BTT arm of the study. The original DT trial design called for enrollment of 200 randomized patients. As of April 27, 2007, 188 patients had been enrolled in the randomized arm of the trial.
The CAP patients will be enrolled and followed under the original protocol of the pivotal trial. The addition of these patients will not impact the timing for the company's planned submission of a PMA (PreMarket Approval) Amendment seeking FDA approval of the HeartMate II for the BTT indication.
- Forums
- ASX - By Stock
- VCR
- fda there is no easy road
VCR
ventracor limited
fda there is no easy road, page-7
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VCR (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online